Literature DB >> 6275999

Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft-tissue surgical sepsis.

H H Stone, C E Geheber, L D Kolb, W E Dunlop.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6275999

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


× No keyword cloud information.
  7 in total

1.  Cost-effective choice of antimicrobial therapy for serious infections.

Authors:  M C Weinstein; J L Read; D N MacKay; J J Kresel; H Ashley; K T Halvorsen; H C Hutchings
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

Review 2.  The third generation cephalosporins.

Authors:  B Farber; R C Moellering
Journal:  Bull N Y Acad Med       Date:  1982-11

3.  Comparison of antibiotic activities by using serum bactericidal activity over time.

Authors:  B J Guglielmo; L C Rodondi
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 4.  A practical guide to the treatment of complicated skin and soft tissue infections.

Authors:  Horatio B Fung; Joanne Y Chang; Stephen Kuczynski
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

6.  A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis.

Authors:  J J Schentag; P B Wels; D P Reitberg; P Walczak; J H Van Tyle; R J Lascola
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.